Cargando…

Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib

OBJECTIVES: Effective therapy for non–small-cell lung cancer (NSCLC) depends on morphological and genomic classification, with comprehensive screening for guideline-recommended biomarkers critical to guide treatment. Companion diagnostics, which provide robust genotyping results, represent an import...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bauml, Joshua M., Li, Bob T., Velcheti, Vamsidhar, Govindan, Ramaswamy, Curioni-Fontecedro, Alessandra, Dooms, Christophe, Takahashi, Toshiaki, Duda, Andrew W., Odegaard, Justin I., Cruz-Guilloty, Fernando, Jin, Liming, Zhang, Ying, Anderson, Abraham, Skoulidis, Ferdinandos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10325630/ https://www.ncbi.nlm.nih.gov/pubmed/34838325 http://dx.doi.org/10.1016/j.lungcan.2021.10.007

Ejemplares similares

Advancing precision oncology in breast cancer: the FDA approval of elacestrant and Guardant360 CDx: a correspondence
por: Abbasi, Haleema Qayyum, et al.
Publicado: (2023)

Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100
por: Dy, Grace K., et al.
Publicado: (2023)

Management of patients with advanced non-small cell lung cancer: role of gefitinib
por: Velcheti, Vamsidhar, et al.
Publicado: (2010)

Sotorasib: First Approval
por: Blair, Hannah A.
Publicado: (2021)

Correction to: Sotorasib: First Approval
por: Blair, Hannah A.
Publicado: (2021)

A Rare Event of Liver Dysfunction on Sotorasib and Management Strategy
por: Kinahan, Holly
Publicado: (2022)

A new era of oncology through artificial intelligence
por: Curioni-Fontecedro, Alessandra
Publicado: (2017)

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab
por: Khunger, Monica, et al.
Publicado: (2017)

Overlapping functions of Cdx1, Cdx2, and Cdx4 in the development of the amphibian Xenopus tropicalis
por: Faas, Laura, et al.
Publicado: (2009)

Cdx1 and Cdx2 Exhibit Transcriptional Specificity in the Intestine
por: Grainger, Stephanie, et al.
Publicado: (2013)

Potential biomarkers uncovered by bioinformatics analysis in sotorasib resistant-pancreatic ductal adenocarcinoma
por: Ramalingam, Prasanna Srinivasan, et al.
Publicado: (2023)

Role of immune-checkpoint inhibitors in lung cancer
por: Jain, Prantesh, et al.
Publicado: (2018)

Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience
por: Khunger, Arjun, et al.
Publicado: (2018)

Case Report: Case series: association between blood concentration and side effects of sotorasib
por: Shigaki, Ryota, et al.
Publicado: (2023)

CDX1 and CDX2 Expression in Intestinal Metaplasia, Dysplasia and Gastric Cancer
por: Kang, Jung Mook, et al.
Publicado: (2011)

Changes in Companion Diagnostic Labelling: Implementation of FDA’s April 2020 Guidance for Industry for In Vitro CDx Labeling for Specific Oncology Therapeutic Groups
por: Cooper, Lisa, et al.
Publicado: (2022)

Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
por: Velcheti, Vamsidhar, et al.
Publicado: (2021)

CodeBreak 200: Sotorasib Has Not Broken the KRAS(G12C) Enigma Code
por: Zhang, Shannon S, et al.
Publicado: (2023)

Is adagrasib just another sotorasib?—or, should we differentiate their usage according to patients’ clinical presentation?
por: Oya, Yuko, et al.
Publicado: (2023)

Transduced caudal‐type homeobox (CDX) 2/CDX1 can induce growth inhibition on CDX‐deficient gastric cancer by rapid intestinal differentiation
por: Nakayama, Chiemi, et al.
Publicado: (2018)

Focal lung infiltrate complicating PD-1 inhibitor use: A new pattern of drug-associated lung toxicity?
por: Sehgal, Sameep, et al.
Publicado: (2016)

Advancing precision oncology in metastatic colorectal cancer: The food and drug administration approval of foundation one liquid CDx as a companion diagnostic a correspondence
por: Shahnoor, Syeda, et al.
Publicado: (2023)

Integrative Analysis of Pharmacokinetic and Metabolomic Profiles for Predicting Metabolic Phenotype and Drug Exposure Caused by Sotorasib in Rats
por: Du, Ping, et al.
Publicado: (2022)

Relationships Between the Expressions of CDX1 and CDX2 mRNA and Clinicopathologic Features in Colorectal Cancers
por: Kim, Gwang Ha, et al.
Publicado: (2005)

How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere
por: Banna, Giuseppe, et al.
Publicado: (2020)

Reply to Authors
por: Banna, Giuseppe, et al.
Publicado: (2020)

Spotlight on Sotorasib (AMG 510) for KRAS(G12C) Positive Non-Small Cell Lung Cancer
por: Zhang, Shannon S, et al.
Publicado: (2021)

Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
por: Lee, Arnold
Publicado: (2022)

DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRAS(G12C)-mutant cancer
por: Chiou, Li-Wen, et al.
Publicado: (2023)

Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of Sotorasib
por: Nolan, Aoife, et al.
Publicado: (2023)

Tolerability of sotorasib for KRAS positive lung adenocarcinoma patient with pre-existing interstitial pneumonia; A case report
por: Okada, Kohei, et al.
Publicado: (2023)

Outcome of carcinoid heart syndrome in patients enrolled in the SwissNet cohort
por: Grundmann, Eva, et al.
Publicado: (2023)

Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1
por: Velcheti, Vamsidhar, et al.
Publicado: (2022)

The current state of the art and future trends in RAS-targeted cancer therapies
por: Punekar, Salman R., et al.
Publicado: (2022)

Correction to: Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
por: Lee, Arnold
Publicado: (2022)

Addressing Atropisomerism in the Development of Sotorasib, a Covalent Inhibitor of KRAS G12C: Structural, Analytical, and Synthetic Considerations
por: Lanman, Brian A., et al.
Publicado: (2022)

Immunohistochemical Expression of CDX2 in Gastric Carcinoma
por: Sardar, Ahmed Avan, et al.
Publicado: (2022)

Expression of CDX2 in metastatic prostate cancer
por: Guerrieri, C., et al.
Publicado: (2019)

IEEE 80211 handbook: a designer's companion
por: O'Hara, Bob, et al.
Publicado: (2005)

Identification of KRAS(G12C) Mutations in Circulating Tumor DNA in Patients With Cancer
por: Thein, Kyaw Z., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i8d5qo59qt9866urcvll5efagh